| Popis: |
Breast cancer remains the leading case of death in woman between the ages of 30 and 55 in industrialized societies. In premenopausal women, approximately 40% have estrogen receptor negative disease. While usually being resistant to hormonal manipulation, disease of this type is generally highly susceptible to anthracycline based chemotherapy. Indeed, anthracyclines constitute the single most active group of drugs in this disease. As in other malignancies, P-glycoprotein/mdr1-mediated multi-drug resistance to anthracycline chemotherapy emerges as a selected phenotype after breast cancer has undergone drug exposure. Multi-drug resistant breast cancer presents a therapeutic problem particularly suited to antisense oligonucleotide therapy. In the present study, mdr-antisense oligonucleotide therapy is successfully applied in anthracycline-resistant, p-glycoprotein-positive breast cancer cell lines in order to restore anthracycline responsiveness. |
